• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Poll

POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Author(s):

Dermatology Times Staff

Click here to answer this week's poll.

Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Deucravacitinib
Tapinarof cream
Roflumilast cream
Spesolimab (generalized pustular psoriasis)
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
PASI and QoL: A New Approach to Treatment Goals
March 31st 2025

PASI and QoL: A New Approach to Treatment Goals

The Cutaneous Connection: An Inside Look of the Inclusive Atlas
November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Biologics Targeting IL-12, IL-23, and IL-17 Reduce Serious Infections in Older Adults with Psoriatic Disease
March 25th 2025

Biologics Targeting IL-12, IL-23, and IL-17 Reduce Serious Infections in Older Adults with Psoriatic Disease

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Long-Term Safety and Efficacy of Ixekizumab in Japanese Patients with Psoriasis
March 20th 2025

Long-Term Safety and Efficacy of Ixekizumab in Japanese Patients with Psoriasis

Post Hoc Analysis Highlights Zasocitinib’s Efficacy Across Patient Groups
March 19th 2025

Post Hoc Analysis Highlights Zasocitinib’s Efficacy Across Patient Groups

© 2025 MJH Life Sciences

All rights reserved.